Is Revumenib-Revuforj already included in medical insurance?

Revumenib - Revuforj is an innovative targeted drug for acute leukemia (including AML, ALL). It is mainly used to treat adult and pediatric patients carrying KMT2A fusion gene or NPM1 mutation. Its mechanism is to interfere with the proliferation and survival of leukemia cells by selectively inhibiting the abnormal transcriptional activity of KMT2A fusion protein. The emergence of this class of drugs provides new treatment options for patients with acute leukemia who are difficult to fully control with traditional chemotherapy. However, currently in China, Revimenib has not been approved for marketing by the drug regulatory authorities, and therefore is not included in the national medical insurance system.

Since the drug cannot be obtained through formal channels in China, patients who wish to use it can only purchase the US version of the original drug through legal overseas channels. However, overseas original drugs are expensive, with a box of drugs usually costing tens of thousands of dollars, which is a large financial burden for most patients. Therefore, the domestic application of Revimenib is still limited by clinical trials or overseas import channels. At the same time, patients must strictly abide by doctor's prescriptions and international transportation regulations when obtaining drugs to ensure the safety and legality of medication.

Although Revimenib has not yet been included in domestic medical insurance, its overseas clinical research results have shown good efficacy and controllable safety. Especially in patients with acute leukemia with KMT2A rearrangement or NPM1 mutation, it can significantly inhibit the progression of the disease. This has also attracted the attention of domestic academic circles and patient groups, and they look forward to its future domestic launch and inclusion in medical insurance, so that more patients with acute leukemia can receive effective treatment.

In general, Revimenib is not yet on the market in China and is not included in medical insurance. Patients can only rely on overseas channels to obtain the original drug, which is expensive and has limited access. This also means that clinical application is still dominated by research and trials, and widespread use still needs to wait for formal approval and medical insurance coverage.

Reference materials:https://www.drugs.com/monograph/revumenib.html